S. Babar
Free University of Brussels
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by S. Babar.
European Urology | 2010
Thierry Roumeguere; Karim Zouaoui Boudjeltia; S. Babar; Vincent Nuyens; A. Rousseau; Pierre Van Antwerpen; Jean Ducobu; Eric Wespes; Michel Vanhaeverbeek
BACKGROUNDnSildenafil, vardenafil, and tadalafil are phosphodiesterase type 5 inhibitors (PDE5-Is) usually used in the treatment of erectile dysfunction (ED). Previously, we have shown the presence of myeloperoxidase-modified low-density lipoprotein (Mox-LDL) in the penises of patients with ED, and we have shown the impact of Mox-LDL on cyclic monophosphate (cGMP) level. In vitro, Mox-LDL triggered the inflammatory response by increasing the release of both interleukin 8 (IL-8) and tumor necrosis factor alpha (TNF-alpha) by endothelial cells (ECs) and monocytes respectively.nnnOBJECTIVEnTo determine whether or not the three therapeutically PDE5-Is protect against the proinflammatory effects of Mox-LDL or TNF-alpha on ECs.nnnDESIGN, SETTING, AND PARTICIPANTSnECs (EA.hy926) were incubated in the presence of either TNF-alpha (100 pg/ml) or Mox-LDL (200 microg/ml) with each of the three PDE5-Is (1 microM, 5 microM, and 10 microM) respectively. IL-8 production was measured in the supernatant after 48 h of incubation.nnnMEASUREMENTSnAll experiments were repeated at least three times. Statistical analysis was performed with an ANOVA.nnnRESULTS AND LIMITATIONSnTwo-way ANOVA analysis showed that TNF-alpha alone (p<0.001) or Mox-LDL alone (p<0.001) increased IL-8 production. Sildenafil, vardenafil, or tadalafil alone did not generate an increase of IL-8 production. Tadalafil in combination with Mox-LDL and TNF-alpha showed a decrease of IL-8 (p<0.05) compared with sildenafil and vardenafil.nnnCONCLUSIONSnAmong the three available PDE5-Is, tadalafil showed an additional potentially anti-inflammatory effect on relaxation. Those data could be considered for the chronic use of PDE5-Is, but extrapolations of experimental evidence to the clinical setting should be made cautiously.
Biochemical and Biophysical Research Communications | 2004
Nicole Moguilevsky; K. Zouaoui Boudjeltia; S. Babar; Paul Delrée; Ilham Legssyer; Y. Carpentier; M. Vanhaeverbeek; J. Ducobu
Atherosclerosis | 2009
K. Zouaoui Boudjeltia; G. Tragas; S. Babar; A. Moscariello; Vincent Nuyens; P. Van Antwerpen; O. Gilbert; J. Ducobu; D. Brohee; Michel Vanhaeverbeek; A. Van Meerhaeghe
Atherosclerosis Supplements | 2006
M. Vaes; K. Zouaoui Boudjeltia; P. Van Antwerpen; S. Babar; F. Deger; Jean Neve; M. Vanhaeverbeek; J. Ducobu
Archive | 2009
Pierre Van Antwerpen; Marie-Christine Slomianny; Karim Zouaoui Boudjeltia; Valegh Faid; S. Babar; Nicole Moguilevsky; Michel Vanhaeverbeek; Jean Ducobu; Jean Neve; Jean-Claude Michalski
Archive | 2007
Pierre Van Antwerpen; François Dufrasne; Martine Prévost; Karim Zouaoui Boudjeltia; S. Babar; Ilham Legssyer; Patrick Moreau; Nicole Moguilevsky; Michel Vanhaeverbeek; Jean Ducobu; Jean Neve
Journal of BIological inorganic chemistry Supplement | 2007
Pierre Van Antwerpen; Martine Prévost; François Dufrasne; Patrick Moreau; Karim Zouaoui Boudjeltia; Thierry Franck; Stephan S. Kohnen; S. Babar; Nicole Moguilevsky; Michel Vanhaeverbeek; Jean Ducobu; Didier Serteyn; Jean Neve
Atherosclerosis Supplements | 2007
Ilham Legssyer; K. Zouaoui Boudjeltia; S. Babar; Vincent Nuyens; P. Van Antwerpen; M. Vanhaeverbeek; J. Ducobu; D. Brohee
Atherosclerosis Supplements | 2007
P. Van Antwerpen; K. Zouaoui Boudjeltia; François Dufrasne; Ilham Legssyer; S. Babar; Patrick Moreau; Nicole Moguilevsky; Martine Prévost; Jean Neve; J. Ducobu
Archive | 2006
Pierre Van Antwerpen; Karim Zouaoui Boudjeltia; François Dufrasne; Ilham Legssyer; S. Babar; Patrick Moreau; Nicole Moguilevsky; Martine Prévost; Michel Vanhaeverbeek; Jean Neve; Jean Ducobu